Evidence map›Paper›PMID 40624332›Full record

ArticleCommunications medicine2025

Cancer Research Funding in Africa.

Oluwasegun Afolaranmi, Elise M Garton, Olaoluwa Ezekiel Dada, Sehar Salim Virani, Abdul R Shour, Adedayo A Onitilo, Syed Nabeel Zafar

Abstract read
In one paragraph

Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Oluwasegun AfolaranmiCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
Elise M GartonCenter for Global Health, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Olaoluwa Ezekiel DadaCollege of Medicine, University of Ibadan, Ibadan, Nigeria.
Sehar Salim ViraniDepartment of Surgery, Aga Khan University, Karachi, Pakistan.
Abdul R ShourMarshfield Clinic Research Institute, Marshfield Clinic Health System, 1000 N Oak Ave, Marshfield, WI, 54449, USA.
Adedayo A OnitiloMarshfield Clinic Research Institute, Marshfield Clinic Health System, 1000 N Oak Ave, Marshfield, WI, 54449, USA.
Syed Nabeel ZafarDepartment of Surgery, University of Wisconsin-Madison, Madison, WI, USA. zafars@surgery.wisc.edu.ORCID http://orcid.org/0000-0003-3843-9687

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
NCI NIH HHS P30 CA014520U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P30 CA014520-48S4
6 · The paper itself

Abstract

backgroundAfrica is projected to witness the steepest rise in cancer incidence and mortality in the coming decades. Therefore, it is critical to understand the current landscape of cancer research funding to identify key gaps and inform decision-making.

methodsWe conducted a retrospective study of funded cancer research projects involving at least one African country over the 20 years between January 2004 and December 2023. Data was collected from four publicly available databases, namely the International Cancer Research Partnership (ICRP), National Institutes of Health World Research Portfolio Online Reporting Tools (WoRLD RePORT), ClinicalTrials.gov (CTG), and International Clinical Trials Registry Platform (ICTRP). We retrieved data on country, year of funding, cancer types, study types, and funding sources. Furthermore, we used incidence, mortality, and prevalence data to compare the level of funded projects to the burden of disease.

resultsA total of 3047 unique funded projects/grants were reported from all 4 databases, with a consistent rise in the number of funded projects throughout the study period. Egypt and South Africa had the most funded cancer research projects, and 9 (16%) countries had no reported studies. Breast, lung, and cervical cancers received the highest funding allocation. We found that several cancers, notably cervical, prostate, and liver, are relatively underfunded compared to their disease burden. 70% of projects reported in ICRP/WoRLD RePORT were funded by the U.S. NIH. Notably, 40% of studies in CTG/ICTRP reported local funding, with Egypt accounting for 94% of these locally financed studies.

conclusionsThis study provides a comprehensive overview of the current state of cancer research funding in Africa, highlighting notable gaps and critical insights to guide data-driven decision-making.

Identifiers

PMID40624332
PMCPMC12234859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.